Lathrop Investment Management Corp lifted its stake in shares of AbbVie Inc (NYSE:ABBV) by 19.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,173 shares of the company’s stock after buying an additional 1,168 shares during the quarter. Lathrop Investment Management Corp’s holdings in AbbVie were worth $661,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Sawgrass Asset Management LLC increased its holdings in AbbVie by 7.4% during the 4th quarter. Sawgrass Asset Management LLC now owns 409,054 shares of the company’s stock worth $37,711,000 after purchasing an additional 28,134 shares during the last quarter. Johnson Financial Group Inc. increased its holdings in AbbVie by 61.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 37,592 shares of the company’s stock worth $3,555,000 after purchasing an additional 14,242 shares during the last quarter. Tradition Capital Management LLC increased its holdings in AbbVie by 3.7% during the 4th quarter. Tradition Capital Management LLC now owns 91,197 shares of the company’s stock worth $8,407,000 after purchasing an additional 3,247 shares during the last quarter. Coastline Trust Co increased its holdings in AbbVie by 1.0% during the 4th quarter. Coastline Trust Co now owns 21,251 shares of the company’s stock worth $1,959,000 after purchasing an additional 201 shares during the last quarter. Finally, Guinness Asset Management Ltd increased its holdings in AbbVie by 33.2% during the 4th quarter. Guinness Asset Management Ltd now owns 220,210 shares of the company’s stock worth $20,301,000 after purchasing an additional 54,840 shares during the last quarter. Institutional investors and hedge funds own 70.66% of the company’s stock.

In related news, VP Brian L. Durkin sold 475 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $79.69, for a total transaction of $37,852.75. Following the completion of the transaction, the vice president now owns 9,121 shares in the company, valued at approximately $726,852.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $80.00, for a total value of $2,000,000.00. Following the transaction, the insider now owns 139,838 shares of the company’s stock, valued at approximately $11,187,040. The disclosure for this sale can be found here. Insiders have sold a total of 41,272 shares of company stock valued at $3,286,290 in the last 90 days. Insiders own 0.08% of the company’s stock.

Several research analysts have recently commented on the company. Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Tuesday, January 8th. Standpoint Research assumed coverage on AbbVie in a research report on Wednesday, December 26th. They issued a “buy” rating for the company. Argus lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Barclays reiterated a “hold” rating and issued a $86.00 target price on shares of AbbVie in a research report on Thursday, February 14th. Finally, Credit Suisse Group set a $79.00 target price on AbbVie and gave the stock a “hold” rating in a research report on Friday, January 25th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $94.48.

Shares of ABBV opened at $77.57 on Monday. The company has a market capitalization of $114.42 billion, a PE ratio of 9.81, a PEG ratio of 1.38 and a beta of 1.16. AbbVie Inc has a 52 week low of $75.77 and a 52 week high of $107.25.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.92 by ($0.02). AbbVie had a net margin of 17.36% and a negative return on equity of 439.07%. The company had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. Research analysts expect that AbbVie Inc will post 8.68 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $1.07 per share. The ex-dividend date is Friday, April 12th. This represents a $4.28 dividend on an annualized basis and a yield of 5.52%. AbbVie’s dividend payout ratio is currently 54.11%.

ILLEGAL ACTIVITY NOTICE: “Lathrop Investment Management Corp Has $661,000 Position in AbbVie Inc (ABBV)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/lathrop-investment-management-corp-has-661000-position-in-abbvie-inc-abbv/2980530.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Read More: How mutual funds make money

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.